Connectivity Alterations After Levetiracetam Application

Beijing Neurosurgical Institute

Status: Unknown

Conditions: Glioma; Epilepsy

Study type: Observational

Funder types: Other

Identifiers

NCT04425798

KY 2019-038-03

Details and patient eligibility

About

This study aimed to analyze the connectivity alterations in brain networks of LGG patients with epilepsy who take levetiracetam at short-term preoperatively.

Full description

Glioma-related epilepsy (GRE) is a very common symptom in patients with diffuse gliomas. Approximately 60% of patients with low-grade gliomas (LGGs) and 40-64% of patients with high-grade gliomas presented with GRE at the onset. Although beneficial for the control of GRE, the overall therapeutic effect was unsatisfied and over 20% of patients still suffered from seizures.

GRE was found to be associated with brain network and functional connectivity. And it has been reported that temporal lobe seizures could induce functional connectivity and decreased network efficiency of brain networks. However, the alterations in functional networks induced by GRE were still unclear. And LGG patients with GRE usually take levetiracetam (LEV) preoperatively, which could effectively reduce abnormal spike activity and further cause connectivity alterations. This makes it more complex to reveal the connectivity alterations of brain networks in LGG patients with GRE.

This study aimed to collect the resting-state functional MRIs of 30 LGG patients who presented with GRE at the onset. Through further applied graph theory analysis, investigators tend to reveal the connectivity alterations of brain networks caused by levetiracetam. The findings of this study will provide a theoretical basis for further study of connectivity alterations of brain networks in patients with GRE.

Enrollment: 30 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age ≥ 18 years;
• Histopathological diagnosis with LGG according to the 2016 World Health Organization (WHO) criteria;
• Participants received more than 6 years of school education;
• Presence of GRE, take levetiracetam less than 1 month; or do not take any medicine and receive any treatment;
• No history of biopsy, radiotherapy, or chemotherapy.

Exclusion criteria

• Contraindications for MRI;
• Head motion greater than 3 mm in translation or 3° in rotation;

Trial design

30 participants in 2 patient groups

Patients with LEV application

Description:

LGG patients with GRE take levetiracetam less than 1 month preoperatively. These patients take levetiracetam tablets twice a day, and one tablet at a time. Each levetiracetam tablet contains 500mg levetiracetam.

Patients without LEV application

Description:

LGG patients with GRE do not take any medicine or receive any treatment preoperatively.